Universal Genetic Testing for Cancer Risk Reduction
NYU Langone Health
Summary
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Eligibility
- Age range
- 25–39 years
- Sex
- Female
- Healthy volunteers
- Yes
Inclusion Criteria: 1. Female patients between ages of 25-39 years at the time of visit 2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol. Exclusion Criteria: 1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers 2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable) 3. History of bilateral salpingo-oophorectomy 4. Visit related to pregnancy or immediately postpartum (within 2 weeks)
Interventions
- GeneticNatera® Empower™ hereditary cancer panel test
The test will be the Natera® Empower™ hereditary cancer panel test and will be collected by saliva.
- OtherSpecialist Referral
Participants with actionable pathogenic variants will be referred to the appropriate specialists (e.g., medical oncologist, gynecologic oncologist, breast surgeon) to discuss risk-reduction strategies and offered genetic counseling
Location
- NYU Langone HealthNew York, New York